FOR IMMEDIATE RELEASE
December 23, 2020

 

STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
Phone: (919) 903-2057
Email: kevin.scorsone@ncoda.org
www.ncoda.org

MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED

NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it was announced late last month. The model would negatively affect patient access to Part B drugs – the anti-cancer (oral and infused) treatments that are administered in oncology practices.

Today, it was announced that US District Court Judge Catherine Blake (Maryland) issued a two-week temporary restraining order (TRO) which delays the implementation of the MFN model. The two-week reprieve allows the court time to consider implementing a preliminary injunction against the MFN model.

This mandatory 7-year payment model would establish reimbursement to providers based on an MFN price for the 50 highest cost Part B drugs. The MFN price would be phased in to replace the current ASP reimbursement model and would be based on international pricing from other similar countries.

This model would create a potentially insurmountable challenge for oncology practices, and it would hurt the people who matter most – the patients. NCODA continues to oppose this model and will monitor and update our membership as progress is made on this decision.

Michael Reff, RPh, MBA
Founder & Executive Director | NCODA, Inc.

Read the full release HERE.

Read More

FOR IMMEDIATE RELEASE
December 18, 2020
STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF

Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison
Phone: (919) 903-2057
Email:
kevin.scorsone@ncoda.org
https://www.ncoda.org

MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS

NCODA is in opposition of the Most Favored Nation (MFN) model for Medicare patients that would negatively affect patient access to Part B drugs – the chemotherapy and infusion treatments that are administered in our community oncology member practices.

Scheduled to begin January 1, 2021, this mandatory 7-year payment model proposed to lower drug costs would establish reimbursement to providers based on an MFN price for the 50 highest cost Part B drugs.  The MFN price would be phased in to replace the current ASP reimbursement model and would be based on international pricing from other countries.

Under the MFN model, practices administering these drugs would be purchasing and administering these drugs at a cost exceeding the proposed MFN reimbursement.  These losses would be unsustainable and force practices to close their doors and send patients to more expensive treatment locations. Life-saving treatment options would not be as readily available to many seniors who would be forced to forgo treatment.

We are still in the midst of the COVID-19 pandemic which has resulted in thousands of deaths. The MFN model will promote additional limitations on seniors’ access to standard of care therapy for their cancer diagnoses.

NCODA does not support the implementation of this mandatory model on cancer patients and the oncology community. Not only would this model create a potentially insurmountable challenge for oncology practice it would hurt the people who matter most, the patient.

Our Passion for Patients is not just a statement it continues to be our Mission and focus.


Michael Reff, RPH, MBA
Founder and Executive Director

Full Press Release HERE

Read More

FOR IMMEDIATE RELEASE
December 11, 2020
STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF

Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison
Phone: (919) 903-2057
Email:
kevin.scorsone@ncoda.org
https://www.ncoda.org


SUPREME COURT RULES UNANIMOUS: REGULATES PHARMACY BENEFIT MANAGERS
Decision confirms that states will have the right to regulate; brings clarity and optimism

Yesterday, December 10, 2020, the United States Supreme Court (Rutledge, Attorney General of Arkansas VS Pharmaceutical Care Management Association) unanimously decided that states can regulate Pharmacy Benefit Managers. Pharmacy Benefit Managers (PBM’s) are companies that oversee the prescription drug benefits on behalf of insurance companies along with Medicare Part D drug plans.

NCODA believes that this decision by the Supreme Court marks a significant day for pharmacists and pharmacies everywhere. Most importantly, this ruling provides patients the ability to have complete transparency when dealing with Pharmacy Benefit Managers and track the cost of their medications.

Read the full press release here.

Read More

Download Here 

This PQI will discuss the initiation and management of patients receiving avapritinib

Background:

Avapritinib is a tyrosine kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. Avapritinib was approved in January 2020 and is the first therapy approved for patients with GIST with a PDGFRA exon 18 mutation. The NAVIGATOR trial included patients with a confirmed diagnosis of GIST and received 300 mg or 400 mg orally once daily until disease progression or unacceptable toxicity. Patients starting at 400 mg were later reduced to 300 mg due to toxicity. The primary endpoint was overall response rate (ORR), and 43 patients who had exon 18 PDGFRA mutations were included in the ORR analysis. For GIST patients with PDGFRA exon 18 mutations, ORR was 84% with complete response in 7% of patients and partial response in 77% of patients. Patients with PDGFRA D842V mutations had an ORR of 89% (CR 8% and PR 82%; n=38). There were 22 patients with a PDGFRA exon 18 mutation with a duration of response  6 months (61%) and 20 patients with a PDGFRA D842V mutation with a duration of response  6 months (59%). Dose reduction due to an adverse reaction occurred in 49% of patients who received avapritinib with a median time to dose reduction of 9 weeks.  The most common adverse reactions (≥ 20%) were edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash, and dizziness.1

PQI Process:

  • Confirm diagnosis and Verify genetic testing for PDGFRA exon 18 and PDGFRA D842V mutations for patients with GIST

Upon receiving a prescription for avapritinib:

  • Recommended dosage is 300mg orally once daily on an empty stomach, as least one hour before and two hours after a meal
    • No dose adjustment recommended with mild/moderate renal or mild/moderate hepatic impairment
    • Dose modifications:
First dose reduction200mg once daily
Second dose reduction100mg once daily
Third dose reductionPermanently discontinue in patients unable to tolerate 100 mg daily.
  • Assess patient for antiemetic regimen; consider regular option for patient use as needed
  • Avoid avapritinib administration with strong or moderate CYP3A inhibitors. If combination with moderate CYP3A4 is unavoidable, reduce dose of avapritinib to 100 mg once daily.
  • Avoid avapritinib administration with strong or moderate CYP3A inducers.
  • Dose modifications for specific adverse reactions:
    • Intracranial Hemorrhage
      • Grade 1 or 2:
        • First Occurrence: Withhold avapritinib until resolution and resume at reduced dose
        • Subsequent Occurrence: Discontinue
      • Grade 3 or 4: Permanently discontinue
    • Central Nervous System Effects:
      • Grade 1:
        • Continue avapritinib at same dose or withhold until improvement to baseline or resolution. Resume at same dose or reduced dose
      • Grade 2 or 3:
        • Withhold avaprintinib until improvement to baseline, grade 1, or resolution. Resume at same or reduced dose.
      • Grade 4: Discontinue
    • Other adverse reactions at Grade 3 or 4:
      • Withhold avapritinib until improvement to less than or equal to Grade 2. Resume at same or reduced dose, as clinically appropriate.

Patient Centered Activities:

  • Provide Oral Chemotherapy Education Sheet
  • Counsel patient that medication should be taken on empty stomach
  • Educate patient that a missed dose needs to be taken within 8 hours of the regular dosing time.
  • Counsel patient on potential drug interactions with avapritinib
  • Monitor patient for central nervous side effects such as dizziness, trouble sleeping, changes in mood or behavior as well as any neurological signs and symptoms related with intracranial hemorrhage
    • Educate the patient and their caregiver network to be alert for cognitive changes such as memory loss, forgetfulness and confusion
  • Monitor patient for laboratory changes associated with common adverse reactions such as decreased hemoglobin and increased bilirubin

Supplemental Information:

  • Patient Support Program: YourBlueprint (https://www.yourblueprint.com/hcp/)
    • Dedicated Case Manager available at 1-888-258-7768 (1-888-BLUPRNT)
    • Monday-Friday 8AM-8PM ET
  • Co-Pay Assistance Program
    • Eligible, commercially insured patients may reduce their out-of-pocket costs (as much as $0 per month)

References:

  1. AYVAKITTM (avapritinib) [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; January 2020.
  2. Heinrich MC, Jones RL, von Mehren M et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open- label, phase 1 trial. Lancet Oncol. 2020 Jul;21(7):935-946.
Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional.  This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented.  NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

 

Read More

Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Download Here 

Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is FDA approved as a targeted therapy for BRCA-mutated breast cancer, ovarian, and pancreatic cancer as well as prostate cancer.  This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.

Background: 

Breast Cancer

About 5-10% of breast cancers can be associated with gene mutations inherited from a parent, most commonly mutations in the BRCA1 and BRCA2 genes.

Lifetime Risk of Developing Breast Cancer
MutationWomenMen
BRCA1Up to 72%6.8%
BRCA269%Less frequent cause

Ovarian Cancer

Currently, ovarian cancer is primarily treated with surgery and systemic chemotherapy. About 22% of ovarian cancer cases are related to a BRCA mutation (15% germline and 7% somatic).14,15

Pancreatic Cancer

Up to 7% of patients with pancreatic cancer have a gBRCA mutation. 16,17

Prostate Cancer

Olaparib approved in May 2020 for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (Full indication list in Supplemental Information)

PQI Process: 

  • Verify the dosage form is correct
  • Olaparib was previously available as both a tablet and a capsule, and the two dosage forms had different bioavailability and therefore were not interchangeable on a milligram-per-milligram The capsules were discontinued as of August 2018, and only the tablets are currently available.
  • Olaparib is available as 100 mg and 150 mg tablets.
  • Verify the dose is correct
  • Typical starting dose for all FDA-approved indications: 300 mg orally twice daily
    • See Supplemental Information Section for current FDA-approved indications
  • The dose of olaparib must be adjusted to 200 mg twice daily for renal dysfunction when creatinine clearance is <50 mL/minute. Olaparib has not been studied in patients with creatinine clearance < 30 mL/minute.
  • Dose adjustments for adverse reactions
  • Consider holding treatment or dose reductions if patients experience adverse reactions.
Dose reductionRecommended DoseHow to Supply
1st dose reduction250 mg BIDOne 150 mg tablet + one 100 mg tablet BID
2nd dose reduction200 mg BIDTwo 100 mg tablets BID
  • Drug interactions
  • Avoid concomitant use with moderate and/or strong CYP3A4 inhibitors
  • If a strong CYP3A4 inhibitor must be used concomitantly, the olaparib dose should be reduced to 100 mg twice daily.
  • If a moderate CYP3A4 inhibitor must be used concomitantly, the olaparib dose should be reduced to 150 mg twice daily.
  • Avoid concomitant strong CYP3A inducers; if a moderate CYP3A inducer must be used, there is the potential for reduced efficacy of olaparib.
  • Laboratory monitoring
  • Complete blood counts should be performed at baseline and monthly thereafter
  • Renal function should be verified at baseline and periodically thereafter

Patient Centered Activities:

  • Provide Oral Chemotherapy Education Sheet
  • Storage: Olaparib should be stored at room temperature and protected from moisture
  • Handling: though not on the NIOSH list, Olaparib is considered hazardous due to its toxicity profile. Appropriate handling should be advised.
  • Instruct patient to avoid grapefruit, grapefruit juice, Seville oranges, and/or Seville orange juice.

Copay Assistance:

  • Commercially insurance patients who qualify can enroll in a $0 copay card assistance program through AstraZeneca’s Access 360 program: www.MyAccess360.com

References:

  1. Birrer, M. Ask an expert: how do PARP inhibitors work? Cancer Updates, Research & Education. Published March 27, 2018.
  2. Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199-203.
  3. How common are BRCA mutations? INSIGHT from Dana-Farber Cancer Institute. Updated March 1, 2018. Available at: https://blog.dana-farber.org/insight/2018/03/
    brca-mutations-common.
  4. How do PARP inhibitors work in cancer? INSIGHT from Dana-Farber Cancer Institute. July 2016. Available at: https://blod.dana-farber.org/insight/2016/07/how-do-parp-inhibitors-work-in-cancer.
  5. Key statistics for ovarian cancer. American Cancer Society. Last updated January 8, 2019. Accessed April 8, 2019. Available at: https://www.cancer.org/cancer/ovarian-cancer/ about/key-statistics.html.
  6. Lexicomp Online, Hudson, Ohio: Lexi-Comp, Inc.; updated 2/22/19; accessed 2/25/19.
  7. LYNPARZA® (olaparib) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
  8. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med2018; 379:2495-2505.
  9. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2018. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#ovarian
  10. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncology; 2017:18(9):1274-1284.
  11. Robson M, Im A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCAmutation (OlympiAD trial). N Engl J Med. 2017; 377:523-533.
  12. S. Breast Cancer Statistics. Breastcancer.org. Last updated Feb 13,2019. Accessed Mar 19, 2019. Available at: www.breastcancer.org/symptoms/understand_bc/statistics.
  13. Konstantinopoulos et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer. J Clin Oncol
  14. Pal T et al. Cancer. 2005;104(12):2807-2816.
  15. Pennington KP et al. Clin Cancer Res. 2014;20(3):764-775.
  16. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma. V.1.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 20, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
  17. SEER Cancer Stat Fact Sheets: Pancreatic Cancer. National Cancer Institute website. https://seer.cancer.gov/statfacts/html/pancreas.html.  Accessed March 20, 2020. 

Supplemental Information:

Current FDA-approved indications: (Starting dose is 300 mg twice daily for all indications)

IndicationEfficacySafety
Ovarian cancer
First-line maintenance treatment for deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to first-line platinum-based chemotherapy (SOLO-1 trial)·  PFS results (p-value <0.0001): olaparib vs placebo: NR vs 13.8 months

·  70% lower risk of disease progression or death with olaparib than with placebo.

·  Most common AEs with olaparib: nausea, vomiting, fatigue, anemia, diarrhea

·  Serious AEs occurred in 21% of olaparib patients vs 12% of placebo patients, most commonly anemia

In combination with bevacizumab for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:

·       Deleterious or suspected deleterious BRCA mutation and/or

·       Genomic instability

(PAOLA-1 trial)

·  Reduced the risk of disease progression or death by 67% (equal to HR of 0.33) and improved progression-free survival to a median of 37.2 months vs 17.7 months with bevacizumab alone
·  Adverse reactions (Grade 1-4) occurring in ≥10% of patients treated with olaparib/bevacizumab in PAOLA-1 and at ≥5% frequency compared with the placebo/bevacizumab arm were nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%), and leukopenia (18%).

·  Most common adverse reactions (≥10%) for patients receiving olaparib/bevacizumab were diarrhea (18%), neutropenia (18%), urinary tract infection (15%), and headache (14%).

Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to platinum-based chemotherapy (SOLO-2 trial)·  PFS (p-value <0.0001): olaparib vs placebo: 19.1 months vs 5.5 months·  Most common grade 1-2 AEs in both groups: nausea, fatigue, vomiting, abdominal pain, and diarrhea

·  Most common grade 3 or higher AE with olaparib: anemia

Deleterious or suspected deleterious gBRCAm advanced ovarian cancer after > 3 prior lines of chemotherapySingle arm trial PFS results:

·  ORR: 34%

·  Median DoR: 7.9 months

·  Serious AEs reported in 30% of patients, most frequently anemia, abdominal pain, intestinal obstruction, and pleural effusion
Breast Cancer
Deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer after treatment with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting (OlympiAD trial)·  PFS (p-value 0.0009):

·  Olaparib vs chemotherapy: 7 months vs 4.2 months

·  Rate of grade 3 or higher AEs was lower with olaparib (36.6%) vs chemotherapy (50.5%)

·  AEs that occurred more frequently in the olaparib group: anemia, nausea, vomiting, fatigue, headache, and cough

Pancreatic Cancer
Maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

(POLO trial)

·  PFS results (p-value 0.0035): olaparib vs. placebo: median 7.4 months vs. 3.8 months

·  ORR: 23% in olaparib arm (12% in placebo arm)

·  Most common AE at grades 3-4 for olaparib: anemia (11%)

·  All grades AE that were >30%: Fatigue (60%), Nausea (45%), Abdominal pain (34%)

·  All grade Diarrhea at 29%

Prostate Cancer
Treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. (PROfound trial)
·  Reduced risk of disease progression or death by 66% (HR 0.34, p-value <0.0001)

·  Radiographic PFS maiden of 7.4 months vs. 3.6 months with enzalutamide or abiraterone in men with BRCA1/2 or ATM gene-mutated mCRPC

·  Most common AE (Grade 1-4) occurring in ≥10% in the olaparib arm (N=256) were anemia (46%), nausea (41%), fatigue including asthenia (41%), decreased appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%) and dyspnea (10%).1

·  Venous thromboembolic events, including pulmonary embolism occurred in 7% of patients with mCRPC who received olaparib plus androgen deprivation therapy (ADT) compared to 3.1% of patients receiving enzalutamide or abiraterone plus ADT

PFS – progression free survival; AEs – adverse events; ORR – objective response rates; DoR – duration of response

Based on current February 2020 ASCO Guidelines13:

  • Women diagnosed with epithelial ovarian cancer
    • Offer germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes at time of diagnoses
    • First or second-degree blood relatives with a known germline susceptible gene mutation or variant
      • Should be offered individualized genetic risk evaluation/counseling and genetic testing
    • Genetic evaluations can be conducted in conjunction with HCPs including genetic counselors
Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
Read More